US Patent Issued to RACTIGEN THERAPEUTICS on April 21 for "Oligomeric nucleic acid molecule, and application thereof in an acute intermittent porphyria treatment" (Chinese Inventors)

ALEXANDRIA, Va., April 21 -- United States Patent no. 12,605,400, issued on April 21, was assigned to RACTIGEN THERAPEUTICS (Nantong City, China).

"Oligomeric nucleic acid molecule, and application thereof in an acute intermittent porphyria treatment" was invented by Longcheng Li (Nantong City, China) and Moorim Kang (Nantong City, China).

According to the abstract* released by the U.S. Patent & Trademark Office: "The present invention relates to compositions of small activating nucleic acid molecules for increasing the expression of HMBS gene and a use thereof. The small activating nucleic acid molecule can be a double-stranded or single-stranded RNA molecule targeting the promoter region of the HMBS gene. The first nucleic acid strand t...